Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

IM-1617

Antibody-drug conjugate · developed by Immunome

Phase 1 Most advanced trial
IMNM Developer
1 Registered trials

What is IM-1617?

IM-1617 is an antibody-drug conjugate. It is studied in colorectal cancer, non-small cell lung cancer, breast cancer, esophageal cancer, and stomach cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Antibody-drug conjugate
Therapy area
Oncology
Developer
Immunome, Inc. (IMNM)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07578571 Phase 1 Colorectal Cancer Recruiting IMNM

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Breast CancerCancerColorectal CancerEsophageal CancerNon-Small Cell Lung CancerStomach Cancer

More from Immunome

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the IMNM page.

Follow IMNM, the company behind IM-1617

See IMNM's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

IMNM catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.